TherApeutics in Early ProState Cancer (TAPS02)

This trial is testing apalutamide — a drug that blocks male hormones from fueling prostate cancer — in men with early-stage prostate cancer who have chosen active surveillance (watchful waiting) rather than immediate treatment. The goal is to see if a short course of this drug can slow or stop disease progression. **You may be eligible if...** - You are 18 or older with early-stage, low-to-intermediate risk prostate cancer - You have chosen active surveillance as your management plan - You have an MRI-detectable lesion and confirmed cancer from a targeted biopsy - You are in reasonably good health (ECOG 0–2) with adequate organ function **You may NOT be eligible if...** - You have had any prior hormone therapy or androgen receptor-blocking treatment for prostate cancer - You have a history of seizures, recent stroke, brain lesions, or conditions that may trigger seizures - You have significant heart problems, including recent heart attack, severe angina, or blood clots within 6 months - You have uncontrolled high blood pressure - You are taking medications known to cause dangerous heart rhythm problems (QT-prolonging drugs) Talk to your doctor to see if this trial is right for you.